FI125849. Presentation - FinVector Oy. Ark Therapeutics Group plc is an innovative gene-based medicine. company with operations in the UK and Finland. Ark seeks to capitalise. on its pipeline of programmes in high value areas of unmet medical need. within vascular disease and cancer, all of which have originated in its.
The ethos of FinVector's experienced analytical development team is to work with clients through all stages of custom assay development. One of the key services FinVector offers is the aseptic filling of liquid investigational medicinal products (IMPs), or commercial products. FinVector can provide short-term and long-term stability studies